UNSPSC 51141572: Pivagabine

This classification denotes an anticonvulsant agent with the molecular formula C9H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C53SV0WO4V, chemically known as 4-((2,2-dimethylpropionyl)amino)butyric acid but generally known as pivagabine, which bears US NIH Compound Identifier 68888. European Medicines Agency schedules Pivagabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09948MIG.

UNSPSC 51141572 Pivagabine, a Commodity code, nominally denotes a single active pharmaceutical ingredient; however, recent state and local solicitations tagged under this code reflect a much broader pharmaceutical procurement pattern spanning generic multi-source drugs, over-the-counter products, and opioid-reversal agents, not pivagabine specifically. State and local governments use this code tier to solicit pharmaceutical supply contracts through competitive bidding, cooperative purchasing alliances, and exploratory requests for information. Issuing bodies include county health departments, state health agencies, and multistate cooperative purchasing consortia. Seminole County, Florida solicited 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through an IFB, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, and the Texas Health and Human Services Commission issued an RFI to gather vendor capability information for a Therapeutic Pharmacy Initiative focused on direct-to-manufacturer prescription fulfillment.

Recent activity concentrates in Florida, Minnesota, Texas, and Oregon, with the MMCAP cooperative vehicle expanding reach across multiple jurisdictions. The Seminole County IFB (Solicitation Number IFB60459723LAS, due July 26, 2023) required quarterly deliveries to a county health building and included E-Verify compliance, workers' compensation insurance, and a three-month probationary termination clause. The MMCAP RFP (Solicitation Number S1070000015802, due March 26, 2026) established two-year contracts for multiple manufacturers, demanded current Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance, and evaluated proposals 75 percent on price competitiveness with 10 percent on fixed pricing and 5 percent each on administrative fee compliance, EDI capability, and pricing format. The Texas HHS RFI (Solicitation Number HHS0017013, posted April 3, 2026) served as a market-intelligence tool to inform future procurement strategy for direct-to-manufacturer prescription programs without formal award amounts or binding timelines.